Want to see TSE:MIR full AI Analyst Report?
Top Page
Medmira
(MIR)
Select Model
Select Model
Rating:47Neutral
Price Target:
C$0.07
▼(-1.43% Downside)
Action:Reiterated
Date:08/22/26
The score is held down primarily by weak financial performance—persistent losses, negative cash flow, and a stressed balance sheet with negative equity and rising debt—despite strong recent revenue growth. Technical indicators provide some support (price above major moving averages with moderately positive momentum), while valuation is difficult to assess meaningfully due to negative earnings and no dividend yield data.
Positive Factors
Revenue Rebound
The TTM revenue rebound indicates materially stronger product demand and market activity. If sustained, higher sales can improve operating leverage and support scale across healthcare and public-health customers, although profitability conversion remains unproven.
Negative Factors
Persistent Unprofitability
Deeply negative gross margin and continuing operating and net losses show that revenue growth has not yet translated into viable unit economics. Without sustained gross-profit improvement, future scale could increase losses rather than create durable earnings.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Rebound
The TTM revenue rebound indicates materially stronger product demand and market activity. If sustained, higher sales can improve operating leverage and support scale across healthcare and public-health customers, although profitability conversion remains unproven.
Read all positive factors
Medmira (MIR) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$45.61M
Dividend YieldN/A
Average Volume (3M)51.34K
Price to Earnings (P/E)―
Beta (1Y)1.00
Revenue Growth45.72%
EPS Growth35.82%
CountryCA
Employees52
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding701,730,600
10 Day Avg. Volume32,307
30 Day Avg. Volume51,337
Financial Highlights & Ratios
PEG Ratio-0.35
Price to Book (P/B)-2.47
Price to Sales (P/S)232.06
P/FCF Ratio-17.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Medmira Business Overview & Revenue Model
Company Description
MedMira Inc. is a biotechnology company focused on the research, development, manufacturing, and global commercialization of rapid diagnostic solutions and related technology platforms. Its operations span North America, Europe, the Asia Pacific r...
How the Company Makes Money
MedMira makes money primarily by selling diagnostic test kits and related consumables built on its RVF rapid testing platform. Revenue is generated when customers (e.g., clinics, hospitals, laboratories, government/public health agencies, and dist...
Medmira Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
10
Very Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Oct 2025 | Oct 2024 | Oct 2023 | Oct 2022 | Oct 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 370.57K | 240.51K | 412.57K | 432.53K | 952.13K | 2.14M |
| Gross Profit | -1.66M | -990.25K | 226.49K | -434.91K | 304.03K | 1.72M |
| EBITDA | -1.75M | -3.13M | -2.13M | -1.58M | -1.07M | 185.30K |
| Net Income | -2.99M | -4.52M | -3.33M | -2.68M | -1.83M | -675.80K |
Balance Sheet | ||||||
| Total Assets | 3.40M | 3.68M | 6.07M | 3.65M | 3.83M | 3.89M |
| Cash, Cash Equivalents and Short-Term Investments | 0.00 | 14.91K | 2.10M | 13.18K | 33.46K | -2.30M |
| Total Debt | 17.42M | 10.71M | 9.56M | 9.27M | 8.30M | 11.54M |
| Total Liabilities | 27.92M | 26.24M | 24.11M | 18.68M | 16.19M | 19.61M |
| Stockholders Equity | -24.52M | -22.56M | -18.04M | -15.03M | -12.36M | -15.72M |
Cash Flow | ||||||
| Free Cash Flow | -1.19M | -3.15M | -3.68M | -1.27M | -1.95M | -541.19K |
| Operating Cash Flow | -1.19M | -3.15M | -2.94M | -1.27M | -1.88M | -504.64K |
| Investing Cash Flow | 0.00 | -7.47K | -742.53K | -1.27K | -69.72K | -36.55K |
| Financing Cash Flow | 1.17M | 1.07M | 5.77M | 1.25M | 1.99M | 139.32K |
Medmira Technical Analysis
Negative
0.07
Price Trends
0.06
Negative
0.06
Negative
0.06
Negative
Market Momentum
<0.01
Positive
45.54
Neutral
5.56
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MIR, the sentiment is Negative. The current price of 0.07 is above the 20-day moving average (MA) of 0.06, above the 50-day MA of 0.06, and above the 200-day MA of 0.06, indicating a bearish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 45.54 is Neutral, neither overbought nor oversold. The STOCH value of 5.56 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:MIR.
Medmira Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | C$91.14M | 20.98 | 15.04% | 6.94% | 4.11% | 88.39% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | C$40.41M | -8.36 | -18.83% | ― | -27.13% | -1752.63% | |
47 Neutral | C$45.61M | -14.77 | 12.68% | ― | 45.72% | 35.82% | |
46 Neutral | C$46.97M | -5.76 | -334.08% | ― | ― | 19.02% | |
43 Neutral | C$41.54M | -3.13 | 55.85% | ― | ― | 49.13% | |
42 Neutral | C$38.65M | -4.57 | -1661.38% | ― | ― | -40.15% |
* General Sector Average
TSE:MIR
Medmira
0.07
-0.01
-16.67%
TSE:COV
Covalon Technologies
3.30
1.15
53.49%
TSE:MBX
Microbix Biosystms
0.30
0.06
28.26%
TSE:SVA
Sernova
0.11
-0.07
-38.89%
TSE:NRX
NurExone Biologic
0.64
-0.17
-20.99%
TSE:DTC
Defence Therapeutics
0.51
-0.16
-23.88%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.